Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 2751 | 6.95 |
09:34 ET | 100 | 6.97 |
09:39 ET | 300 | 6.95 |
09:41 ET | 100 | 6.9 |
09:45 ET | 1344 | 6.762 |
09:48 ET | 100 | 6.8699 |
09:50 ET | 682 | 6.8057 |
09:52 ET | 4824 | 6.82 |
09:54 ET | 845 | 6.76 |
09:56 ET | 600 | 6.805 |
09:57 ET | 300 | 6.77 |
10:01 ET | 200 | 6.82 |
10:03 ET | 200 | 6.82 |
10:06 ET | 1510 | 6.79 |
10:10 ET | 800 | 6.71 |
10:12 ET | 500 | 6.7 |
10:17 ET | 1030 | 6.68 |
10:19 ET | 200 | 6.65 |
10:21 ET | 2000 | 6.675 |
10:24 ET | 800 | 6.72 |
10:26 ET | 300 | 6.68 |
10:28 ET | 100 | 6.71 |
10:30 ET | 1000 | 6.68 |
10:32 ET | 222 | 6.705 |
10:33 ET | 2594 | 6.68 |
10:35 ET | 301 | 6.62 |
10:37 ET | 726 | 6.665 |
10:42 ET | 656 | 6.65 |
10:44 ET | 114 | 6.65 |
10:46 ET | 300 | 6.68 |
10:48 ET | 100 | 6.61 |
10:50 ET | 1000 | 6.63 |
10:51 ET | 2000 | 6.6433 |
10:53 ET | 200 | 6.64 |
10:55 ET | 100 | 6.64 |
10:57 ET | 400 | 6.62 |
11:00 ET | 200 | 6.64 |
11:04 ET | 100 | 6.61 |
11:06 ET | 200 | 6.61 |
11:08 ET | 6550 | 6.62 |
11:09 ET | 100 | 6.57 |
11:11 ET | 200 | 6.605 |
11:13 ET | 1000 | 6.65 |
11:15 ET | 500 | 6.64 |
11:18 ET | 1300 | 6.61 |
11:20 ET | 300 | 6.63 |
11:22 ET | 615 | 6.66 |
11:31 ET | 200 | 6.62 |
11:33 ET | 600 | 6.66 |
11:36 ET | 200 | 6.68 |
11:38 ET | 1400 | 6.68 |
11:40 ET | 300 | 6.66 |
11:42 ET | 300 | 6.65 |
11:44 ET | 326 | 6.67 |
11:45 ET | 1800 | 6.685 |
11:47 ET | 200 | 6.68 |
11:51 ET | 100 | 6.68 |
11:54 ET | 666 | 6.66 |
11:56 ET | 700 | 6.65 |
12:07 ET | 1000 | 6.65 |
12:09 ET | 284 | 6.665 |
12:20 ET | 100 | 6.665 |
12:34 ET | 100 | 6.631 |
12:36 ET | 300 | 6.63 |
12:43 ET | 100 | 6.58 |
12:48 ET | 2126 | 6.58 |
12:50 ET | 1053 | 6.5799 |
12:54 ET | 200 | 6.58 |
12:56 ET | 100 | 6.58 |
12:57 ET | 300 | 6.62 |
01:01 ET | 1000 | 6.615 |
01:14 ET | 4400 | 6.58 |
01:15 ET | 200 | 6.55 |
01:21 ET | 600 | 6.55 |
01:26 ET | 6157 | 6.56 |
01:30 ET | 100 | 6.555 |
01:32 ET | 100 | 6.555 |
01:33 ET | 400 | 6.57 |
01:35 ET | 500 | 6.58 |
01:37 ET | 100 | 6.58 |
01:39 ET | 100 | 6.605 |
01:42 ET | 100 | 6.585 |
01:44 ET | 1200 | 6.585 |
01:46 ET | 400 | 6.61 |
01:48 ET | 100 | 6.63 |
01:50 ET | 100 | 6.64 |
01:55 ET | 500 | 6.62 |
01:57 ET | 200 | 6.61 |
02:02 ET | 100 | 6.625 |
02:04 ET | 600 | 6.64 |
02:11 ET | 313 | 6.62 |
02:13 ET | 400 | 6.65 |
02:15 ET | 100 | 6.65 |
02:18 ET | 100 | 6.67 |
02:26 ET | 100 | 6.65 |
02:27 ET | 100 | 6.65 |
02:29 ET | 1290 | 6.64 |
02:31 ET | 300 | 6.65 |
02:33 ET | 3540 | 6.68 |
02:38 ET | 8775 | 6.705 |
02:40 ET | 4190 | 6.6898 |
02:44 ET | 100 | 6.69 |
02:45 ET | 666 | 6.675 |
02:47 ET | 449 | 6.675 |
02:49 ET | 300 | 6.63 |
02:51 ET | 100 | 6.66 |
02:54 ET | 100 | 6.63 |
03:00 ET | 100 | 6.64 |
03:03 ET | 675 | 6.635 |
03:05 ET | 1152 | 6.65 |
03:07 ET | 100 | 6.67 |
03:09 ET | 200 | 6.67 |
03:21 ET | 600 | 6.65 |
03:25 ET | 100 | 6.63 |
03:27 ET | 3891 | 6.72 |
03:30 ET | 300 | 6.72 |
03:32 ET | 300 | 6.71 |
03:34 ET | 100 | 6.69 |
03:38 ET | 7394 | 6.7 |
03:39 ET | 100 | 6.7 |
03:41 ET | 2135 | 6.73 |
03:43 ET | 1822 | 6.71 |
03:45 ET | 647 | 6.7 |
03:48 ET | 394 | 6.7 |
03:50 ET | 3150 | 6.71 |
03:52 ET | 4193 | 6.71 |
03:54 ET | 5070 | 6.7 |
03:56 ET | 33666 | 6.65 |
03:57 ET | 1102 | 6.62 |
03:59 ET | 18499 | 6.59 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 137.1M | -0.8x | --- |
Century Therapeutics Inc | 139.8M | -0.8x | --- |
Kodiak Sciences Inc | 136.8M | -0.7x | --- |
Actuate Therapeutics Inc | 135.2M | 0.0x | --- |
Context Therapeutics Inc | 139.5M | -1.8x | --- |
PDS Biotechnology Corp | 134.4M | -3.0x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $137.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.02 |
EPS | $-7.99 |
Book Value | $8.23 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.